Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment
Balance at beginning of period at Dec. 31, 2019	$ 1,143,683	$ (558)	$ 115	$ 1,127,487	$ (19,986)	$ 36,067	$ (558)
Balance at beginning of period (in shares) at Dec. 31, 2019			115,120
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	89,915					89,915
Other comprehensive income (loss)	(13,700)				(13,700)
Dividends declared	(39,441)					(39,441)
Net issuances of restricted stock	0		$ 1	(1)
Net issuances of restricted stock (in shares)			745
Stock-based compensation expense	13,525			13,525
Repurchases of common stock	(63,499)		$ (1)			(63,498)
Repurchases of common stock (in shares)			(1,263)
Balance at end of period at Mar. 31, 2020	1,129,925		$ 115	1,141,011	(33,686)	22,485
Balance at end of period (in shares) at Mar. 31, 2020			114,602
Balance at beginning of period at Dec. 31, 2020	1,205,289		$ 113	1,179,972	(4,732)	29,936
Balance at beginning of period (in shares) at Dec. 31, 2020			113,128
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	110,598					110,598
Other comprehensive income (loss)	(8,797)				(8,797)
Dividends declared	(43,300)					(43,300)
Net issuances of restricted stock	0		$ 1	(1)
Net issuances of restricted stock (in shares)			602
Stock-based compensation expense	14,182			14,182
Repurchases of common stock	(80,273)		$ (1)			(80,272)
Repurchases of common stock (in shares)			(1,048)
Balance at end of period at Mar. 31, 2021	$ 1,197,699		$ 113	$ 1,194,153	$ (13,529)	$ 16,962
Balance at end of period (in shares) at Mar. 31, 2021			112,682